ATE500814T1 - Zusammensetzung enthaltend chitosan sowie ein zuckerphosphat oder ein polyolphosphat - Google Patents

Zusammensetzung enthaltend chitosan sowie ein zuckerphosphat oder ein polyolphosphat

Info

Publication number
ATE500814T1
ATE500814T1 AT05717745T AT05717745T ATE500814T1 AT E500814 T1 ATE500814 T1 AT E500814T1 AT 05717745 T AT05717745 T AT 05717745T AT 05717745 T AT05717745 T AT 05717745T AT E500814 T1 ATE500814 T1 AT E500814T1
Authority
AT
Austria
Prior art keywords
phosphate
polyol
composition containing
sugar
containing chitosan
Prior art date
Application number
AT05717745T
Other languages
English (en)
Inventor
Ann DYER
Patricia Pastor
Lisbeth Illum
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Application granted granted Critical
Publication of ATE500814T1 publication Critical patent/ATE500814T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Consolidation Of Soil By Introduction Of Solidifying Substances Into Soil (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT05717745T 2004-02-21 2005-02-18 Zusammensetzung enthaltend chitosan sowie ein zuckerphosphat oder ein polyolphosphat ATE500814T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0403938.4A GB0403938D0 (en) 2004-02-21 2004-02-21 Chitosan containing solution
PCT/GB2005/000592 WO2005079749A2 (en) 2004-02-21 2005-02-18 Chitosan containing solution

Publications (1)

Publication Number Publication Date
ATE500814T1 true ATE500814T1 (de) 2011-03-15

Family

ID=32040183

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05717745T ATE500814T1 (de) 2004-02-21 2005-02-18 Zusammensetzung enthaltend chitosan sowie ein zuckerphosphat oder ein polyolphosphat

Country Status (7)

Country Link
US (1) US20080248991A1 (de)
EP (1) EP1722759B1 (de)
AT (1) ATE500814T1 (de)
DE (1) DE602005026783D1 (de)
ES (1) ES2420356T3 (de)
GB (1) GB0403938D0 (de)
WO (1) WO2005079749A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1375301A (en) 1999-11-15 2001-05-30 Bio Syntech Canada Inc Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
US20030158302A1 (en) 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
DE60003459T2 (de) * 1999-12-09 2004-05-06 Biosyntech Canada Inc., Laval Mineral-polymer hybrid-zusammensetzung
DK1294414T3 (da) * 2000-06-29 2006-07-24 Biosyntech Canada Inc Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv
EP1790351A4 (de) * 2004-09-15 2009-11-04 Otsuka Pharma Co Ltd Permukosale zusammensetzung und verfahren zur verbesserung der permukosalen absorption
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
WO2007059605A1 (en) * 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
EP2057982A1 (de) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasale Zusammensetzungen
CL2008000156A1 (es) 2008-01-18 2008-08-01 Igloo Zone Chile S A Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
WO2010118516A1 (en) * 2009-04-14 2010-10-21 Globe Laboratories Inc. Compositions for sublingual drug delivery and methods of use thereof
DE102009024542A1 (de) 2009-06-10 2010-12-16 Arivine Pharma Ag Zusammensetzungen auf Basis von Chitosan-Oligosacchariden
WO2012107573A1 (en) * 2011-02-10 2012-08-16 Moberg Derma Ab Novel formulations for dermal, transdermal and mucosal use 3
EP2854764B1 (de) 2012-06-05 2018-12-12 Neuroderm Ltd Zusammensetzungen mit apomorphin und organischen säuren und verwendungen davon
US20150231130A1 (en) 2012-07-26 2015-08-20 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
TWI624270B (zh) * 2013-01-17 2018-05-21 財團法人工業技術研究院 藥物組合物
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9192574B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan paste wound dressing
US9192692B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan stenting paste
US9480828B2 (en) 2013-11-14 2016-11-01 Gyrus Acmi, Inc. Treatment method for the inferior turbinate
US20180133147A1 (en) * 2013-12-19 2018-05-17 Novartis Ag Drug Delivery Systems
SG11201702614SA (en) * 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
NL2022788B1 (en) * 2019-03-22 2020-09-28 No Ceuticals B V Chitosan nitrate for use as a nitric oxide donor (NO donor)
KR102415342B1 (ko) * 2021-07-07 2022-07-04 주식회사 메디팹 다중 가교된 온도감응성 하이드로겔 제조용 조성물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
CA2212300A1 (en) * 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
AU1375301A (en) * 1999-11-15 2001-05-30 Bio Syntech Canada Inc Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
CA2429165A1 (en) * 2000-11-15 2002-05-23 Bio Syntech Canada Inc. Filler composition for soft tissue augmentation and reconstructive surgery

Also Published As

Publication number Publication date
EP1722759B1 (de) 2011-03-09
WO2005079749A2 (en) 2005-09-01
GB0403938D0 (en) 2004-03-24
US20080248991A1 (en) 2008-10-09
WO2005079749A3 (en) 2006-03-23
EP1722759A2 (de) 2006-11-22
ES2420356T3 (es) 2013-08-23
DE602005026783D1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
DE602005026783D1 (en) Erphosphat oder ein polyolphosphat
DE502004007735D1 (en) Flächiges implantat
TWI341201B (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
BRPI0507440A (pt) fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
DK1768490T3 (da) Systemer og fremgangsmåder til ex-vivo-organpleje
ATE510558T1 (de) Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen
ZA200801511B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases
WO2008045021A3 (en) Blood compatible nanomaterials and methods of making and using the same
BR0307564A (pt) Derivados de nicotinamida úteis como inibidores de pde4
DE602004022554D1 (de) Thermische behandlung einer implantierbaren medizinischen arzneimittel-elutions-vorrichtung
NO20083026L (no) Terapeutisk middel for diabetes
WO2009091994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
WO2004072265A3 (en) Methods for monitoring drug activities in vivo
NO20076405L (no) Anvendelse av 24-nor-UDCA
ZA200707560B (en) 5-phenyl-pentanoc acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
DK2046813T3 (da) Proteinbindende methotrexat-derivater og lægemiddel indeholdende disse
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties